Triple therapy viable option for anti-VEGF non-responders

Article

Triple therapy for age-related macular degeneration (AMD) can stabilize vision and reduce the re-treatment rate in patients who do not respond to initial anti-VEGF therapy.

Triple therapy for age-related macular degeneration (AMD) can stabilize vision and reduce the re-treatment rate in patients who do not respond to initial anti-VEGF therapy, according to a poster submitted to the American Society of Retina Specialists 2007 annual meeting.

Allan Franklin, MD and colleagues designed a three-part treatment protocol involving injections of triamcinolone and bevacizumab, followed by short-duration photodynamic therapy (PDT). A total of 27 patients were treated with the protocol.

At one-year follow-up, it was found that approximately 40% of patients required one re-treatment with a combination intravitreal injection and 11% required two to three combination injections or repeated triple therapy. Eleven percent of patients required three or more re-treatments and were considered refractory to triple therapy. Overall, patients demonstrated a stabilization in vision during the first 12 months follow-up.

Fourteen patients were available for a longer follow-up period and, of these, three gained at least three lines of vision, three lost three lines or more and vision remained stable in the remaining eight.

It is thought that triple therapy of this kind could offer a viable option in patients who are not rapid responders to anti-VEGF therapy alone.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.